STOCK TITAN

[Form 4] Intellia Therapeutics, Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Intellia Therapeutics, Inc. (NTLA) – Form 4 insider transaction

EVP & Chief Technical Officer Eliana Clark reported the sale of 1,022 common shares on 01 July 2025 at a price of $9.82 per share (transaction code “S”). The shares had been purchased a day earlier under the company’s 2016 Employee Stock Purchase Plan and were therefore treated as non-derivative shares in Table I.

Following the disposition, Clark’s direct beneficial ownership stands at 95,369 shares. No derivative securities transactions were reported in Table II, and no Rule 10b5-1 trading plan box was checked, indicating the sale was executed outside of a pre-arranged trading program.

The filing represents a 1.1 % reduction in Clark’s directly held position (1,022 / 96,391 pre-sale) and is relatively small in dollar terms (~$10,000). No other insiders are included in this filing, and there is no indication of broader strategic implications for NTLA. Investors typically monitor insider activity for sentiment signals; however, a sale of this size by one executive is generally viewed as routine portfolio management rather than a material change in outlook.

Intellia Therapeutics, Inc. (NTLA) – Transazione insider Form 4

La EVP e Chief Technical Officer Eliana Clark ha segnalato la vendita di 1.022 azioni ordinarie il 1 luglio 2025 a un prezzo di 9,82 $ per azione (codice transazione “S”). Le azioni erano state acquistate il giorno precedente nell'ambito del Piano di Acquisto Azionario per Dipendenti 2016 della società e sono quindi state trattate come azioni non derivate nella Tabella I.

Dopo la vendita, la posizione diretta di Clark è pari a 95.369 azioni. Non sono state riportate transazioni su titoli derivati nella Tabella II e nessuna casella del piano di trading Rule 10b5-1 è stata selezionata, indicando che la vendita è stata eseguita al di fuori di un programma di trading predefinito.

La comunicazione rappresenta una riduzione dell’1,1% della posizione detenuta direttamente da Clark (1.022 / 96.391 pre-vendita) ed è relativamente modesta in termini di valore (~10.000 $). Nessun altro insider è incluso in questa comunicazione e non vi sono indicazioni di implicazioni strategiche più ampie per NTLA. Gli investitori monitorano solitamente l’attività degli insider per segnali di sentiment; tuttavia, una vendita di questa entità da parte di un singolo dirigente è generalmente considerata una normale gestione del portafoglio piuttosto che un cambiamento sostanziale nelle prospettive.

Intellia Therapeutics, Inc. (NTLA) – Transacción de insider Formulario 4

La EVP y Directora Técnica Eliana Clark reportó la venta de 1,022 acciones ordinarias el 1 de julio de 2025 a un precio de $9.82 por acción (código de transacción “S”). Las acciones habían sido compradas un día antes bajo el Plan de Compra de Acciones para Empleados 2016 de la compañía y por ello se trataron como acciones no derivadas en la Tabla I.

Tras la disposición, la propiedad directa beneficiosa de Clark se sitúa en 95,369 acciones. No se reportaron transacciones con valores derivados en la Tabla II, y no se marcó ninguna casilla del plan de trading Rule 10b5-1, lo que indica que la venta se ejecutó fuera de un programa de trading preestablecido.

La presentación representa una reducción del 1.1% en la posición directa de Clark (1,022 / 96,391 antes de la venta) y es relativamente pequeña en términos monetarios (~$10,000). Ningún otro insider está incluido en esta presentación y no hay indicios de implicaciones estratégicas más amplias para NTLA. Los inversores suelen monitorear la actividad de insiders para señales de sentimiento; sin embargo, una venta de este tamaño por parte de un solo ejecutivo generalmente se considera gestión rutinaria de cartera más que un cambio material en la perspectiva.

Intellia Therapeutics, Inc. (NTLA) – Form 4 내부자 거래

EVP 겸 최고기술책임자 Eliana Clark2025년 7월 1일1,022주 보통주 매도를 주당 $9.82 가격으로 보고했습니다(거래 코드 “S”). 해당 주식은 회사의 2016년 직원 주식 구매 계획에 따라 하루 전에 매수되어 표 I에서 파생되지 않은 주식으로 처리되었습니다.

매도 후 Clark의 직접 보유 지분은 95,369주입니다. 표 II에는 파생 증권 거래가 보고되지 않았으며, Rule 10b5-1 거래 계획 박스도 선택되지 않아 사전 설정된 거래 프로그램 외부에서 매도된 것으로 보입니다.

이번 신고는 Clark의 직접 보유 지분에서 1.1% 감소를 나타내며(매도 전 96,391주 대비 1,022주), 금액으로는 비교적 적은 약 1만 달러 규모입니다. 다른 내부자는 이번 신고에 포함되지 않았으며, NTLA에 대한 광범위한 전략적 영향은 없음을 시사합니다. 투자자들은 일반적으로 내부자 활동을 감정 신호로 주시하지만, 단일 임원의 이 정도 규모 매도는 일상적인 포트폴리오 관리로 간주되는 경우가 많습니다.

Intellia Therapeutics, Inc. (NTLA) – Transaction d’initié Formulaire 4

La EVP et Directrice Technique Eliana Clark a déclaré la vente de 1 022 actions ordinaires le 1er juillet 2025 au prix de 9,82 $ par action (code transaction « S »). Ces actions avaient été achetées la veille dans le cadre du Plan d’Achat d’Actions Employés 2016 de la société et ont donc été traitées comme des actions non dérivées dans le Tableau I.

Après cette cession, la détention directe bénéficiaire de Clark s’élève à 95 369 actions. Aucune transaction sur titres dérivés n’a été signalée dans le Tableau II, et aucune case du plan de trading Rule 10b5-1 n’a été cochée, indiquant que la vente a été réalisée hors d’un programme de trading préétabli.

Cette déclaration représente une réduction de 1,1 % de la position détenue directement par Clark (1 022 / 96 391 avant la vente) et est relativement modeste en termes de valeur (~10 000 $). Aucun autre initié n’est inclus dans ce dépôt, et il n’y a aucune indication d’implications stratégiques plus larges pour NTLA. Les investisseurs surveillent généralement l’activité des initiés pour détecter des signaux de sentiment ; toutefois, une vente de cette ampleur par un seul dirigeant est généralement considérée comme une gestion de portefeuille de routine plutôt qu’un changement significatif de perspective.

Intellia Therapeutics, Inc. (NTLA) – Insider-Transaktion Form 4

EVP & Chief Technical Officer Eliana Clark meldete den Verkauf von 1.022 Stammaktien am 1. Juli 2025 zu einem Preis von 9,82 $ pro Aktie (Transaktionscode „S“). Die Aktien wurden einen Tag zuvor im Rahmen des Mitarbeiteraktienkaufplans 2016 des Unternehmens erworben und daher in Tabelle I als nicht-derivative Aktien behandelt.

Nach der Veräußerung beträgt Clarks direkter wirtschaftlicher Besitz 95.369 Aktien. In Tabelle II wurden keine Transaktionen mit derivativen Wertpapieren gemeldet, und kein Rule-10b5-1-Handelsplan wurde markiert, was darauf hinweist, dass der Verkauf außerhalb eines vorab vereinbarten Handelsprogramms erfolgte.

Die Meldung stellt eine Reduzierung um 1,1 % von Clarks direkt gehaltenem Bestand dar (1.022 / 96.391 vor dem Verkauf) und ist in Dollarwerten relativ gering (~10.000 $). Keine weiteren Insider sind in dieser Meldung enthalten, und es gibt keine Hinweise auf weitergehende strategische Implikationen für NTLA. Investoren beobachten Insider-Aktivitäten üblicherweise als Stimmungsindikatoren; ein Verkauf dieser Größenordnung durch eine Führungskraft wird jedoch meist als routine Portfolioverwaltung angesehen und nicht als wesentliche Änderung der Perspektive.

Positive
  • None.
Negative
  • Insider disposition: EVP & CTO sold 1,022 shares, registering a small but negative sentiment signal, albeit immaterial in scale.

Insights

TL;DR: Minor CTO share sale; negligible impact on NTLA valuation.

The Form 4 discloses a modest disposition (1,022 shares, ~$10k) by EVP & CTO Eliana Clark. With ~95k shares still held, her economic exposure remains substantial. The lack of a 10b5-1 plan suggests discretionary timing, but the <1.5 % reduction is too small to infer negative corporate sentiment. I view the filing as immaterial to earnings forecasts or valuation models. Trading volumes for NTLA routinely exceed 500k shares daily, so market impact should be de minimis.

TL;DR: Routine insider sale; governance posture unchanged.

Insider transactions are useful sentiment gauges, yet this isolated, low-value sale does not raise red flags. Clark remains a significant shareholder, aligning her incentives with long-term investors. The company continues to disclose under standard Section 16 requirements, indicating sound compliance. I categorize the overall governance impact as neutral.

Intellia Therapeutics, Inc. (NTLA) – Transazione insider Form 4

La EVP e Chief Technical Officer Eliana Clark ha segnalato la vendita di 1.022 azioni ordinarie il 1 luglio 2025 a un prezzo di 9,82 $ per azione (codice transazione “S”). Le azioni erano state acquistate il giorno precedente nell'ambito del Piano di Acquisto Azionario per Dipendenti 2016 della società e sono quindi state trattate come azioni non derivate nella Tabella I.

Dopo la vendita, la posizione diretta di Clark è pari a 95.369 azioni. Non sono state riportate transazioni su titoli derivati nella Tabella II e nessuna casella del piano di trading Rule 10b5-1 è stata selezionata, indicando che la vendita è stata eseguita al di fuori di un programma di trading predefinito.

La comunicazione rappresenta una riduzione dell’1,1% della posizione detenuta direttamente da Clark (1.022 / 96.391 pre-vendita) ed è relativamente modesta in termini di valore (~10.000 $). Nessun altro insider è incluso in questa comunicazione e non vi sono indicazioni di implicazioni strategiche più ampie per NTLA. Gli investitori monitorano solitamente l’attività degli insider per segnali di sentiment; tuttavia, una vendita di questa entità da parte di un singolo dirigente è generalmente considerata una normale gestione del portafoglio piuttosto che un cambiamento sostanziale nelle prospettive.

Intellia Therapeutics, Inc. (NTLA) – Transacción de insider Formulario 4

La EVP y Directora Técnica Eliana Clark reportó la venta de 1,022 acciones ordinarias el 1 de julio de 2025 a un precio de $9.82 por acción (código de transacción “S”). Las acciones habían sido compradas un día antes bajo el Plan de Compra de Acciones para Empleados 2016 de la compañía y por ello se trataron como acciones no derivadas en la Tabla I.

Tras la disposición, la propiedad directa beneficiosa de Clark se sitúa en 95,369 acciones. No se reportaron transacciones con valores derivados en la Tabla II, y no se marcó ninguna casilla del plan de trading Rule 10b5-1, lo que indica que la venta se ejecutó fuera de un programa de trading preestablecido.

La presentación representa una reducción del 1.1% en la posición directa de Clark (1,022 / 96,391 antes de la venta) y es relativamente pequeña en términos monetarios (~$10,000). Ningún otro insider está incluido en esta presentación y no hay indicios de implicaciones estratégicas más amplias para NTLA. Los inversores suelen monitorear la actividad de insiders para señales de sentimiento; sin embargo, una venta de este tamaño por parte de un solo ejecutivo generalmente se considera gestión rutinaria de cartera más que un cambio material en la perspectiva.

Intellia Therapeutics, Inc. (NTLA) – Form 4 내부자 거래

EVP 겸 최고기술책임자 Eliana Clark2025년 7월 1일1,022주 보통주 매도를 주당 $9.82 가격으로 보고했습니다(거래 코드 “S”). 해당 주식은 회사의 2016년 직원 주식 구매 계획에 따라 하루 전에 매수되어 표 I에서 파생되지 않은 주식으로 처리되었습니다.

매도 후 Clark의 직접 보유 지분은 95,369주입니다. 표 II에는 파생 증권 거래가 보고되지 않았으며, Rule 10b5-1 거래 계획 박스도 선택되지 않아 사전 설정된 거래 프로그램 외부에서 매도된 것으로 보입니다.

이번 신고는 Clark의 직접 보유 지분에서 1.1% 감소를 나타내며(매도 전 96,391주 대비 1,022주), 금액으로는 비교적 적은 약 1만 달러 규모입니다. 다른 내부자는 이번 신고에 포함되지 않았으며, NTLA에 대한 광범위한 전략적 영향은 없음을 시사합니다. 투자자들은 일반적으로 내부자 활동을 감정 신호로 주시하지만, 단일 임원의 이 정도 규모 매도는 일상적인 포트폴리오 관리로 간주되는 경우가 많습니다.

Intellia Therapeutics, Inc. (NTLA) – Transaction d’initié Formulaire 4

La EVP et Directrice Technique Eliana Clark a déclaré la vente de 1 022 actions ordinaires le 1er juillet 2025 au prix de 9,82 $ par action (code transaction « S »). Ces actions avaient été achetées la veille dans le cadre du Plan d’Achat d’Actions Employés 2016 de la société et ont donc été traitées comme des actions non dérivées dans le Tableau I.

Après cette cession, la détention directe bénéficiaire de Clark s’élève à 95 369 actions. Aucune transaction sur titres dérivés n’a été signalée dans le Tableau II, et aucune case du plan de trading Rule 10b5-1 n’a été cochée, indiquant que la vente a été réalisée hors d’un programme de trading préétabli.

Cette déclaration représente une réduction de 1,1 % de la position détenue directement par Clark (1 022 / 96 391 avant la vente) et est relativement modeste en termes de valeur (~10 000 $). Aucun autre initié n’est inclus dans ce dépôt, et il n’y a aucune indication d’implications stratégiques plus larges pour NTLA. Les investisseurs surveillent généralement l’activité des initiés pour détecter des signaux de sentiment ; toutefois, une vente de cette ampleur par un seul dirigeant est généralement considérée comme une gestion de portefeuille de routine plutôt qu’un changement significatif de perspective.

Intellia Therapeutics, Inc. (NTLA) – Insider-Transaktion Form 4

EVP & Chief Technical Officer Eliana Clark meldete den Verkauf von 1.022 Stammaktien am 1. Juli 2025 zu einem Preis von 9,82 $ pro Aktie (Transaktionscode „S“). Die Aktien wurden einen Tag zuvor im Rahmen des Mitarbeiteraktienkaufplans 2016 des Unternehmens erworben und daher in Tabelle I als nicht-derivative Aktien behandelt.

Nach der Veräußerung beträgt Clarks direkter wirtschaftlicher Besitz 95.369 Aktien. In Tabelle II wurden keine Transaktionen mit derivativen Wertpapieren gemeldet, und kein Rule-10b5-1-Handelsplan wurde markiert, was darauf hinweist, dass der Verkauf außerhalb eines vorab vereinbarten Handelsprogramms erfolgte.

Die Meldung stellt eine Reduzierung um 1,1 % von Clarks direkt gehaltenem Bestand dar (1.022 / 96.391 vor dem Verkauf) und ist in Dollarwerten relativ gering (~10.000 $). Keine weiteren Insider sind in dieser Meldung enthalten, und es gibt keine Hinweise auf weitergehende strategische Implikationen für NTLA. Investoren beobachten Insider-Aktivitäten üblicherweise als Stimmungsindikatoren; ein Verkauf dieser Größenordnung durch eine Führungskraft wird jedoch meist als routine Portfolioverwaltung angesehen und nicht als wesentliche Änderung der Perspektive.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Clark Eliana

(Last) (First) (Middle)
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130

(Street)
CAMBRIDGE MA 02139

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Technical Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 S(1) 1,022 D $9.82 95,369 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Sale of 1,022 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025.
/s/ James Basta, attorney-in-fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many NTLA shares did EVP Eliana Clark sell on 01 July 2025?

1,022 common shares were sold at $9.82 each.

What is Eliana Clark’s remaining NTLA shareholding after the sale?

She directly owns 95,369 shares following the reported transaction.

Was the NTLA insider sale executed under a Rule 10b5-1 plan?

No. The filing does not indicate use of a Rule 10b5-1 trading plan.

Does the Form 4 include any derivative security transactions?

No derivative securities were acquired or disposed of in this filing.

Is the 1,022-share sale considered material for NTLA investors?

The transaction represents roughly 1 % of the insider’s holdings and is generally viewed as immaterial.
Intellia Therape

NASDAQ:NTLA

NTLA Rankings

NTLA Latest News

NTLA Latest SEC Filings

NTLA Stock Data

1.11B
98.09M
5.05%
91.72%
25.15%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CAMBRIDGE